Pseudomonas infections of the lung treated with azlocillin. Microbiology, pharmacokinetics, clinic.
6-[(R)-2-(2-Oxo-imidazolidine-1-carboxamido)-2-phenyl-acetamido]-penicillanic acid sodium salt (azlocillin, Securopen), has a special activity against Pseudomonas species besides is broadspectrum character. We confirmed the high in vitro potency of that antibiotic in 200 clinical Pseudomonas isolates. Good penetration of azlocillin into bronchial secretions was found, especially through the inflamed bronchial mucosa, but also in the post-inflammatory phase. In 16 patients with serious Pseudomonas infections of the respiratory tract the good efficacy of azlocillin was shown. There were no tolerance problems.
D001390:Azlocillin; D001980:Bronchi / Q000378:metabolism; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D008171:Lung Diseases / Q000188:drug therapy*; D010406:Penicillins / Q000378:metabolism / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013997:Time Factors
D005839:Gentamicins; D010406:Penicillins; D001390:Azlocillin